Infinity Pharmaceuticals | INFI - Cash And Equivalent


Infinity Pharmaceuticals reported $17.75M in Cash and Equivalent for its fiscal quarter ending in June of 2023.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Amgen USD 9.13B 316M Dec/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Cipla INR 7.96B 39.9M Sep/2025
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 7.46M 985K Sep/2025
CSL USD 2.16B 633M Jun/2025
Eisai JPY 301.65B 16.27B Sep/2025
Eli Lilly USD 7.27B 2.52B Dec/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Grifols EUR 979.78M 334.84M Dec/2024
Incyte USD 3.58B 650.78M Dec/2025
Infinity Pharmaceuticals USD 17.75M 7.99M Jun/2023
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
J&J USD 19.71B 1.48B Dec/2025
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Plus Therapeutics USD 8.55M 2.45M Dec/2023
Roche Holding CHF 7.55B 579M Jun/2025
TG Therapeutics USD 178.32M 100.54M Sep/2025